TORONTO--(BUSINESS WIRE)--Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new brand name Remdantry TM ...

Crohn’s Disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract with relapsing and remitting episodes. It is a disease that progresses over time, leading to complications such as ...

Switching between infliximab biosimilar SB2 and the reference product did not affect clinical disease activity or safety in IBD patients. No significant changes were observed in clinical outcomes, ...